AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

Launched by ASSOCIATION FRANCAISE D'UROLOGIE · Aug 4, 2021

Keywords

ClinConnect Summary

The AFU Registry study is looking at how to improve the treatment and follow-up care for patients with a condition called non-muscle-invasive bladder cancer (NMIBC). This is a type of bladder cancer that hasn't spread deeply into the bladder wall. The goal of the trial is to gather information from urologists who are part of the AFU (French Urological Association) to understand better how these patients are being treated and monitored.

To participate in this study, you would need to have been diagnosed with NMIBC or a specific type of low-risk bladder tumor, which can be confirmed through a procedure that removes tumors from the bladder. Unfortunately, if you have a different type of bladder tumor, you wouldn’t qualify for this trial. While the study is not yet recruiting participants, it aims to collect valuable data that could lead to better care for people dealing with this condition in the future. If you are eligible, you can expect to share your treatment experiences and follow-up information with the researchers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary molecular test (biomarker) prior to their resection (biopsy) diagnosis or recurrence,
• • AND adult (equal to or \> 18 years old),
• • AND affiliated with a social security scheme in France,
• • AND whose monitoring will be carried out at the recruiting center.
• Exclusion Criteria:
• • Patient being monitored for a non-urothelial bladder tumor
• • Patient refusing follow-up
• • Opposition to participation in the study
• • Adult protected by law